A rare form of pancreatic cancer possibly led Steve Jobs to give up his position as CEO of Apple, USA TODAY reports.
Given the employment work ethic and dedication to their work, doctors say his decision to resign suggests that you should feel badly, USA Today he wrote. "Given his desire to dominate, you have to speculate that there may be good," James Abbruzzese, Pancreatic cancer expert at MD Anderson Cancer Center in Houston, USA TODAY says.
Although it is unclear how Jobs will do, "I think we will not talk about survival more years, Zev Wainberg, an oncologist tract [not connected to this case] with the UCLA Jonsson Cancer Center, USA TODAY said.
Jobs, who is suffering from pancreatic neuroendocrine tumors, have been a series of aggressive treatments, such as liver transplantation. He is survived longer than many others with the disease.
Margaret Tempero, pancreatic cancer expert at the University of California-San Francisco and former president of the American Society of Clinical Oncology, said that cancer of the pancreas as U.S. Jobs is generally most common curable, and patients the most common form of the disease often live less than a year.
But unless the disease is completely eradicated, the cancer finally took a turn for the worse, growing much faster, Wainberg told the newspaper.
According to Richard Goldberg, an expert in neuroendocrine tumors of the University of North Carolina-Chapel Hill, "People can live side by side with this disease for many years," but if the liver begins to fail, "people can go down very quickly . When you hit the wall, you hit the wall, "USA TODAY reports.
Doctors do not know what causes neuroendocrine tumors, Abbruzzese said the newspaper, but the most common types of pancreatic cancer associated with smoking and obesity, and possibly a diet full of fat and red meat. Chronic inflammation of the pancreas and exposure to certain chemicals can also cause disease.
They have an increased risk of pancreatic cancer in men, African-Americans, people over the age of 50 years, diabetics and those with a family history of pancreatic cancer.
Researchers are exploring ways to find the disease in the past, families who are looking at the history of a disease. Researchers are also looking for genes that may play an important role in the development of pancreatic cancer. In January, researchers at Johns Hopkins University in Baltimore reported open the genetic code of neuroendocrine tumors, which they hope will lead to better treatments.
This year, the FDA approved two new drugs for neuroendocrine tumors, sunitinib and everolimus.